Bristol Myers Squibb (BMY) Net Income - Minority (2009 - 2024)
Bristol Myers Squibb (BMY) reported Net Income - Minority of -$58.0 million for Q3 2024, down 7.41% on a QoQ basis from -$54.0 million in Q2 2024.
Bristol Myers Squibb (BMY) has 15 years of Net Income - Minority data on file, last reported at -$58.0 million in Q3 2024.
- Quarterly Net Income - Minority changed N/A year-over-year to -$58.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$58.0 million (changed N/A YoY) and the FY2023 annual result came in at -$55.0 million, changed N/A from the prior year.
- Net Income - Minority eased to -$58.0 million in Q3 2024 per BMY's latest filing, from -$54.0 million in the prior quarter.
- Across five years, Net Income - Minority topped out at -$54.0 million in Q2 2024 and bottomed at -$72.0 million in Q3 2020.
- The 4-year median for Net Income - Minority is -$66.0 million (2020), against an average of -$63.6 million.
- The widest annual swing landed in 2020, when Net Income - Minority jumped 40.0%; it then retreated 3.03% in 2021.
- Tracing BMY's Net Income - Minority over 4 years: stood at -$60.0 million in 2020, then slipped by 18.33% to -$71.0 million in 2021, then climbed by 22.54% to -$55.0 million in 2023, then slipped by 5.45% to -$58.0 million in 2024.
- Per Business Quant, the three latest BMY Net Income - Minority figures stand at -$58.0 million (Q3 2024), -$54.0 million (Q2 2024), and -$55.0 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -58.00 Mn |
| Jun 30, 2024 | -54.00 Mn |
| Dec 31, 2023 | -55.00 Mn |
| Sep 30, 2021 | -71.00 Mn |
| Jun 30, 2021 | -66.00 Mn |
| Mar 31, 2021 | -68.00 Mn |
| Dec 31, 2020 | -60.00 Mn |
| Sep 30, 2020 | -72.00 Mn |
| Jun 30, 2020 | -66.00 Mn |
| Mar 31, 2020 | -66.00 Mn |
| Dec 31, 2019 | -100.00 Mn |
| Sep 30, 2019 | -106.00 Mn |
| Jun 30, 2019 | -102.00 Mn |
| Mar 31, 2019 | -99.00 Mn |
| Dec 31, 2018 | -96.00 Mn |
| Sep 30, 2018 | -110.00 Mn |
| Jun 30, 2018 | -101.00 Mn |
| Mar 31, 2018 | -113.00 Mn |
| Dec 31, 2017 | -106.00 Mn |
| Sep 30, 2017 | -131.00 Mn |
| Jun 30, 2017 | -122.00 Mn |
| Mar 31, 2017 | -119.00 Mn |
| Dec 31, 2016 | -170.00 Mn |
| Sep 30, 2016 | -168.00 Mn |
| Jun 30, 2016 | -160.00 Mn |
| Mar 31, 2016 | -165.00 Mn |
| Dec 31, 2015 | -158.00 Mn |
| Sep 30, 2015 | -194.00 Mn |
| Jun 30, 2015 | -168.00 Mn |
| Mar 31, 2015 | -143.00 Mn |
| Dec 31, 2014 | -131.00 Mn |
| Sep 30, 2014 | -58.00 Mn |
| Jun 30, 2014 | -52.00 Mn |
| Mar 31, 2014 | -58.00 Mn |
| Dec 31, 2013 | -82.00 Mn |
| Sep 30, 2013 | 12.00 Mn |
| Jun 30, 2013 | -2.00 Mn |
| Mar 31, 2013 | -40.00 Mn |
| Dec 31, 2012 | -15.00 Mn |
| Jun 30, 2012 | 286.00 Mn |
| Dec 31, 2011 | 89.00 Mn |
| Dec 31, 2010 | 75.00 Mn |
| Dec 31, 2009 | 58.00 Mn |